Department of Internal Medicine III, Division of Gastroenterology/Hepatology, Medical University of Innsbruck, Vienna, Austria.
Hepatology. 2013 Jun;57(6):2224-34. doi: 10.1002/hep.26057. Epub 2013 Jan 18.
We investigated the prognostic value of C-reactive protein (CRP) in patients with hepatocellular carcinoma (HCC) not amenable to surgery. A total of 615 patients diagnosed with HCC not amenable to surgery between April 1999 and December 2009 at the Department of Gastroenterology of the Medical Universities of Vienna and Innsbruck were included. We assessed the optimal CRP cutoff by regression spline analysis and tested its impact on median overall survival (OS) by the Kaplan-Meier method, univariate analysis (log-rank test), and multivariate analysis (Cox proportional hazard regression model) in a training cohort (n = 466, Vienna) and an independent validation cohort (n = 149, Innsbruck). We found a sigmoid-shaped association of CRP and the hazard ratio of death upon regression spline analysis and defined a CRP level <1/≥1 mg/dL as optimal cutoff for further survival assessments. Elevated CRP (≥1 mg/dL) at diagnosis was associated with poor OS (CRP-elevated versus CRP-normal; 4 versus 20 months; P < 0.001) and remained a significant negative predictor for OS upon multivariate analysis (hazard ratio, 1.7; P < 0.001), which was independent of age, Child-Pugh class, tumor characteristics, and treatment allocation. Analyses with respect to Barcelona Clinic Liver Cancer (BCLC) stage and Child-Pugh class supported the relevance of CRP (BCLC-stage C and Child-Pugh A: OS for CRP-elevated versus CRP-normal, 6 versus 14; P < 0.001; BCLC-stage C and Child-Pugh B: OS for CRP-elevated versus CRP-normal, 4 versus 15 months; P < 0.001). The prognostic significance of elevated CRP was reproducible at a second CRP determination timepoint and confirmed in the independent validation cohort.
Elevated CRP is associated with a dismal prognosis in HCC patients and may become a useful marker for patient selection in HCC management. (HEPATOLOGY 2012).
我们研究了 C 反应蛋白(CRP)在不适宜手术的肝细胞癌(HCC)患者中的预后价值。
我们纳入了 1999 年 4 月至 2009 年 12 月在维也纳和因斯布鲁克的两所医学大学胃肠病学系诊断为不适宜手术的 HCC 患者共 615 例。我们通过回归样条分析确定最佳 CRP 截断值,并通过 Kaplan-Meier 法、单因素分析(log-rank 检验)和多因素分析(Cox 比例风险回归模型)在训练队列(n = 466,维也纳)和独立验证队列(n = 149,因斯布鲁克)中检测其对中位总生存(OS)的影响。我们通过回归样条分析发现 CRP 与死亡风险之间呈“S”形关联,并将 CRP 水平 <1/≥1mg/dL 定义为进一步生存评估的最佳截断值。诊断时 CRP 升高(≥1mg/dL)与 OS 不良相关(CRP 升高组与 CRP 正常组;4 个月与 20 个月;P < 0.001),且在多因素分析中仍是 OS 的显著负预测因子(风险比,1.7;P < 0.001),与年龄、Child-Pugh 分级、肿瘤特征和治疗分配无关。关于巴塞罗那临床肝癌(BCLC)分期和 Child-Pugh 分级的分析支持 CRP 的相关性(BCLC 分期 C 和 Child-Pugh A:CRP 升高组与 CRP 正常组的 OS,6 个月与 14 个月;P < 0.001;BCLC 分期 C 和 Child-Pugh B:CRP 升高组与 CRP 正常组的 OS,4 个月与 15 个月;P < 0.001)。在第二个 CRP 测定时间点,CRP 升高的预后意义可重现,并在独立验证队列中得到证实。
CRP 升高与 HCC 患者的不良预后相关,可能成为 HCC 管理中患者选择的有用标志物。